NCT05212025View on ClinicalTrials.gov

Adavosertib and Gemcitabine in Advanced Pancreatic

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2022

Primary Completion Date

June 1, 2023

Study Completion Date

December 31, 2023

Conditions
Pancreatic Cancer
Interventions
DRUG

Adavosertib

Taken Orally

DRUG

Gemcitabine

Intravenous Infusion

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Lustgarten Foundation

OTHER

collaborator

Stand Up To Cancer

OTHER

lead

James Cleary, MD, PhD

OTHER

NCT05212025 - Adavosertib and Gemcitabine in Advanced Pancreatic | Biotech Hunter | Biotech Hunter